See you at #AAIC24 tomorrow! C-Path's Critical Path for Alzheimer's Disease Consortium team is on site at the Alzheimer's Association® #AAIC24 in Philadelphia! Visit us at booth 1340 to connect with our experts: Klaus Romero, Diane Stephenson, Martijn Muller, Yashmin Karten, Anna-Marika Bauer, MRA, Colleen Jacobsen and Eileen Priest. CPAD accelerates the development of patient-centric therapies for Alzheimer's disease by creating new, regulatory-endorsed drug development tools. These tools, built on the latest scientific insights and supported by a comprehensive database of patient-level clinical trial data, enhance our expertise in clinical trial design. We look forward to discussing how we can collaborate to advance Alzheimer's research and improve patient outcomes. Come by booth #1340! #CPath #Alzheimers #drugdevelopment #datasharing #clinicaltrials #globalhealth #collaboration #AD
Critical Path Institute (C-Path)
Research Services
Tucson, AZ 7,836 followers
Advancing Drug Development. Improving Lives. Together.
About us
Critical Path Institute (C-Path) is an independent, nonprofit established in 2005 as a public-private partnership, in response to the FDA’s Critical Path Initiative. C-Path’s mission is to lead collaborations that advance better treatments for people worldwide. Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path’s global headquarters is located in Tucson, Arizona and C-Path’s Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit c-path.org.
- Website
-
http://www.c-path.org/
External link for Critical Path Institute (C-Path)
- Industry
- Research Services
- Company size
- 51-200 employees
- Headquarters
- Tucson, AZ
- Type
- Nonprofit
- Founded
- 2005
- Specialties
- creating collaborations with regulators, patient advocacy groups and the regulated pharmaceutical industry, accelerated development of safer, new medical products, faster, safer, and smarter medical product development, and public private partnership
Locations
-
1840 E River Rd # 100
Tucson, AZ 85718, US
-
Barbara Strozzilaan 201 1083 HN
Amsterdam, NL
Employees at Critical Path Institute (C-Path)
-
Deb Discenza (she/her/hers)
-
Thomas Morel
Global Patient-Centred Outcomes Research & Policy Lead at UCB
-
Huong Huynh Reagan
Regulatory Director | Regulatory endorsements of drug development tools | Cross-functional collaborations | Diverse disease portfolio | Lead people;…
-
Hannah Blau
Data Scientist ∙ ML / NLP Engineer ∙ Listener Extraordinaire ∙ She who does not let stuff fall through the cracks
Updates
-
Interested in C-Path updates? Be sure to subscribe at https://lnkd.in/g37dvFDu For 20 years, C-Path has been providing vital infrastructure to generate a neutral environment for everyone working in drug development to collaborate, not compete. Let's improve lives, together. #CPath #drugdevelopment #neutral #datasharing #globalhealth #collaboration #regulatoryscience
-
Register Now for the Inaugural C-Path Global Impact Conference Join us from September 9-11 in Washington D.C. for the inaugural C-Path Global Impact Conference. This event presents a unique opportunity to engage with leading experts in drug development and to integrate valuable insights across C-Path’s comprehensive portfolio, including neurology, rare diseases, pediatrics, and more. Secure your spot today: https://lnkd.in/g4TqwJVR #CPath #CGIC2024 #GlobalImpactConference #drugdevelopment #datasharing #collaboration #neurology #pediatrics #raredisease
-
-
C-Path is proud to announce the publication of a new study in Alzheimer’s & Dementia: The Journal of the Alzheimer's Association®, led by our Critical Path for Alzheimer’s Disease consortium. This study addresses a major obstacle in comparing investigational tau imaging results across Alzheimer’s disease clinical trials. Alzheimer’s disease is a progressive neurodegenerative condition and a major cause of cognitive decline and behavioral changes. Every 67 seconds, someone in the U.S. develops AD, with nearly 500,000 new cases expected this year. The disease is marked by amyloid and tau proteins, which lead to neurodegeneration. Recent advancements in AD therapeutics have resulted in the approval of disease-modifying treatments targeting amyloid plaques. These treatments also show promise in reducing tau levels, as shown by PET scans. Tau PET imaging is increasingly used in clinical research and trials for AD therapies. Read the full details here: https://lnkd.in/gRevHY2Q Klaus Romero Diane Stephenson Yashmin Karten Gregory Klein Antoine Leuzy Lars Lau Raket Hartmuth Kolb #CPath #AlzheimersResearch #ClinicalTrials #ImagingBiomarkers #Neurology #HealthcareInnovation #drugdevelopment #datasharing #globalhealth #AAIC24
-
-
Next week, C-Path's Critical Path for Alzheimer's Disease Consortium team will be on site at the Alzheimer's Association® International Conference (#AAIC24) in Philadelphia! Visit us at booth 1340 to connect with our experts: Klaus Romero, Diane Stephenson, Martijn Muller, Yashmin Karten, Anna-Marika Bauer, MRA, Colleen Jacobsen and Eileen Priest. CPAD accelerates the development of patient-centric therapies for Alzheimer's disease by creating new, regulatory-endorsed drug development tools. These tools, built on the latest scientific insights and supported by a comprehensive database of patient-level clinical trial data, enhance our expertise in clinical trial design. We look forward to discussing how we can collaborate to advance Alzheimer's research and improve patient outcomes. See you at #AAIC24! #CPath #Alzheimers #drugdevelopment #datasharing #clinicaltrials #globalhealth #collaboration #AD
-
We are proud to be part of a significant advancement in the fight against Parkinson's disease today. What an honor to collaborate with the Digital Medicine Society (DiMe) and The Michael J. Fox Foundation for Parkinson's Research on the expansion of the Library of Digital Measurement Products. This expansion now includes 94 additional digital solutions, supporting Parkinson's disease research, fostering innovation, and improving patient care worldwide. C-Path's Critical Path for Parkinson’s Consortium is dedicated to improving the lives of those affected by Parkinson's disease by accelerating drug development and consistently incorporating the patient voice throughout the process. 🔗 Explore the expanded library here: https://bit.ly/3A0Mers 🔗Learn more about the Critical Path for Parkinson's Consortium here: https://lnkd.in/gH7vqiW4 Klaus Romero Diane Stephenson Martijn Muller #CPath #DiMe #MichaelJFox #Parkinsons #ParkinsonsResearch #Collaboration #DigitalHealth #collaboration #datasharing #drugdevelopment
🎉 DATAcc by DiMe is proud to announce a significant milestone in the fight against Parkinson's disease (PD)! 🤝 With our partners at The Michael J. Fox Foundation for Parkinson's Research and the Critical Path Institute (C-Path)'s Critical Path for Parkinson’s consortium, we have expanded our Library of Digital Measurement Products by integrating 94 additional digital solutions that support Parkinson's disease (PD) research and care. This collaboration enhances the existing resources of the library, providing a more comprehensive toolset for the PD community. 🛠️ Due to diverse and fluctuating symptoms, designing patient-centric digital interventions and therapeutics for PD can be challenging. Sensor-based digital health technologies (sDHTs) bridge this gap by enabling remote and frequent measurement of PD symptoms, supporting early intervention, innovative treatments, and improved patient outcomes. 📚 The expanded library supports clinicians, researchers, and developers with validated tools and streamlined evidence to advance digital health strategies and accelerate the path to improved patient outcomes. 🌐 As part of the expansion of digital solutions to support PD research and care, we have also enhanced the library with a user-friendly interface and intuitive user journey to enable faster, more efficient access to tailored digital health solutions. The library features meaningful concepts of physical activity (PA), Parkinson’s Disease (PD), Sleep, and Alzheimer’s disease and related dementias (ADRD). 💪 This collaboration represents a pivotal step forward in PD research and patient care and exemplifies the power of working collectively to address complex health challenges. We are grateful to our partners for their collaboration and shared vision in advancing digital health solutions for Parkinson's disease. 🔗 Explore the expanded library here: https://bit.ly/3A0Mers
-
-
C-Path's Critical Path for Lysosomal Diseases Consortium today proudly announced the addition of Chiesi Group as a member. The partnership marks a significant milestone in the CPLD’s mission to accelerate drug development for lysosomal diseases and improve the lives of individuals affected by these rare conditions. “We are pleased to join the CPLD Consortium and take part in this important collaborative effort to help address the significant unmet medical needs affecting people living with LDs,” said Giacomo Chiesi, MBA, head of Chiesi Global Rare Diseases. “Driven by our deep commitment to advancing sustainable therapeutic options for rare diseases including LDs, we look forward to working closely with the consortium to support innovation and progress in LD drug development.” Learn the full details here: https://lnkd.in/gGSawnJq Amanda Klein Krista Casazza #CPath #ChiesiGroup #raredisease #lysosomal #collaboration #drugdevelopment #datasharing #globalhealth
-
-
C-Path’s T1D Consortium and Quantitative Medicine Program assisted the team University of Florida with the creation of a clinical trial simulation tool and corresponding article titled "Type 1 Diabetes Prevention Clinical Trial Simulator: Case Reports of Model-informed Drug Development Tool." The article was recently published in CPT: Pharmacometrics & Systems Pharmacology and focuses on the development of a disease progression model-based CTS tool using individual-level data collected from multiple sources. The goal of this tool is to help design more efficient clinical trials that will prevent or delay the onset of T1D. Within the article, the tool is described in depth along with instructions on how to use the tool and case studies. ⏩ Access the article here: https://lnkd.in/gd8mefC3 ⏩ The web-based tool is publicly available here: https://lnkd.in/g_aFYKWk ⏩ Information on C-Path's T1DC here: https://lnkd.in/g9s6mzJ7 Juan Francisco Morales Jagdeep Podichetty, PhD Jackson Burton Klaus Romero Inish O'Doherty, Ph.D. Sarah Kim Sarah David ASCPT Journal Family #CPath #T1D #ASCPTJournalFamily #PSPJournal #drugdevelopment #datasharing #collaboration #globalhealth #diabetes
-
-
Interested in C-Path updates? Be sure to subscribe at https://lnkd.in/gyhN4vac For 20 years, C-Path has been providing vital infrastructure to generate a neutral environment for everyone working in drug development to collaborate, not compete. Let's improve lives, together. #CPath #drugdevelopment #neutral #datasharing #globalhealth #collaboration #regulatoryscience
Subscribe to C-Path News
https://c-path.org
-
Thank you to BizTucson Magazine and News 4 Tucson - KVOA for featuring C-Path in their "The World is Watching Tucson" feature and coverage. As we celebrate 20 years of impact and collaborations, C-Path remains a trusted and neutral partner, leading efforts to generate tools and solutions that de-risk and accelerate the drug development process. https://lnkd.in/gfNBVyT8 #CPath #BizTucson #KVOA #Tucson #Arizona #drugdevelopment #collaboration #partnership #datasharing
Critical Path Institute plays a major role in advancing drug development globally
kvoa.com